APP and Alzheimer disease: Notably, WT161 dramatically increased the expression of ADAM10, a crucial enzyme in the nonamyloidogenic APP processing pathway that cleaves APP to soluble APP-alpha (sAPPa), in the cerebral cortex of AD animals (Fig. 8).